Research Analysts Offer Predictions for Syros Pharmaceuticals, Inc.’s FY2021 Earnings (SYRS)
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Research analysts at Oppenheimer Holdings cut their FY2021 earnings estimates for shares of Syros Pharmaceuticals in a note issued to investors on Wednesday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will post earnings of $1.07 per share for the year, down from their prior estimate of $1.10.
SYRS has been the subject of a number of other reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $30.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Wedbush reissued an “outperform” rating and issued a $22.84 target price (down from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. JMP Securities lowered shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Cowen and Company reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $26.14.
ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/11/research-analysts-offer-predictions-for-syros-pharmaceuticals-inc-s-fy2021-earnings-syrs.html.
Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.28 during mid-day trading on Friday, hitting $11.34. 88,900 shares of the company were exchanged, compared to its average volume of 90,089. Syros Pharmaceuticals has a 1 year low of $10.22 and a 1 year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.53).
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC boosted its stake in Syros Pharmaceuticals by 11.9% during the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after buying an additional 418,061 shares during the period. Redmile Group LLC boosted its stake in Syros Pharmaceuticals by 2.2% during the second quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock worth $15,660,000 after buying an additional 20,520 shares during the period. Vanguard Group Inc. boosted its stake in Syros Pharmaceuticals by 189.6% during the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after buying an additional 250,507 shares during the period. State Street Corp boosted its stake in Syros Pharmaceuticals by 176.7% during the second quarter. State Street Corp now owns 169,497 shares of the company’s stock worth $2,728,000 after buying an additional 108,250 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Syros Pharmaceuticals by 15.9% during the third quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock worth $1,926,000 after buying an additional 17,330 shares during the period. 59.76% of the stock is owned by institutional investors.
In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,282 shares of Syros Pharmaceuticals stock in a transaction on Monday, August 14th. The shares were sold at an average price of $22.00, for a total transaction of $72,204.00. Following the completion of the transaction, the director now directly owns 420,101 shares of the company’s stock, valued at $9,242,222. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 33.60% of the stock is owned by insiders.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.